Mineralys Therapeutics, Inc. 4

Mineralys Therapeutics CMO James J. Ferguson III received 102,400 RSUs and 135,000 stock options as equity awards on August 10, 2026.

On August 10, 2026, Mineralys Therapeutics, Inc. Chief Medical Officer James J. Ferguson III received equity compensation consisting of 102,400 restricted stock units and 135,000 stock options, both reported as acquisitions at no cash cost to the insider. The RSUs each represent a contingent right to receive one share of common stock and will vest over four years in equal annual installments, while the stock option, with an exercise price of $27.38 per share, will vest 25% on the first anniversary of grant and the remaining 75% in 36 substantially equal monthly installments thereafter. Following these grants, Ferguson beneficially owns 135,000 shares of common stock (or equivalent rights) directly, reflecting a significant equity incentive position intended to align his interests with shareholders rather than an open-market transaction.

Filing Facts

CIK

1933414

Ticker

MLYS

Form

4

Source Type

fda

Accession

0001933414-26-000120

Alert Tier

6